» Articles » PMID: 23216038

Outcome of Urethral Stent Placement for Management of Urethral Obstruction Secondary to Transitional Cell Carcinoma in Dogs: 19 Cases (2007-2010)

Overview
Date 2012 Dec 11
PMID 23216038
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the outcome in dogs undergoing urethral stent placement for management of urethral obstruction secondary to transitional cell carcinoma (TCC).

Design: Retrospective case series.

Animals: 19 dogs with histopathologically confirmed TCC.

Procedures: Information regarding urethral stent placement and follow-up treatment was obtained from review of medical records. Quality of life assessment was performed with an owner questionnaire.

Results: Self-expanding nitinol stents were successfully placed in 17 of 19 dogs; stent placement was not possible in one dog, and another dog was euthanatized 2 days after stent placement, but before discharge from the hospital. Median survival time in 17 dogs following successful long-term stent placement was 78 days (range, 2 to 366 days). Complications following stent placement in 18 dogs included incontinence (n = 7), reobstruction from continued growth of urethral TCC (3), acute reobstruction shortly after the procedure (1), and stent migration (2). Of the 17 owners surveyed, 16 were satisfied with the outcome and would recommend urethral stent placement.

Conclusions And Clinical Relevance: The placement of self-expanding nitinol urethral stents was successful in alleviating TCC-induced urethral obstruction and providing good quality of life for most dogs.

Citing Articles

Outcomes of total cystectomy with medical treatment in canine urothelial carcinoma of the bladder trigone.

Takahashi Y, Kato D, Maeda S, Motegi T, Fujita A, Hashimoto Y Can Vet J. 2025; 66(3):318-326.

PMID: 40070938 PMC: 11891803.


Use of the subcutaneous ureteral bypass device and urethral stenting for treatment of malignant urinary outflow tract obstructions in cats.

Covo M, Berent A, Weisse C J Feline Med Surg. 2024; 26(9):1098612X241262666.

PMID: 39344788 PMC: 11459477. DOI: 10.1177/1098612X241262666.


ACVIM consensus statement on diagnosis and management of urinary incontinence in dogs.

Kendall A, Byron J, Westropp J, Coates J, Vaden S, Adin C J Vet Intern Med. 2024; 38(2):878-903.

PMID: 38217372 PMC: 10937496. DOI: 10.1111/jvim.16975.


Antimicrobial and Antiproliferative Coatings for Stents in Veterinary Medicine-State of the Art and Perspectives.

Graczyk S, Paslawski R, Grzeczka A, Paslawska U, Swieczko-Zurek B, Malisz K Materials (Basel). 2023; 16(21).

PMID: 37959431 PMC: 10649059. DOI: 10.3390/ma16216834.


Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.

Ciriano Cerda E, Zajc A, Finotello R, MacDonald K, Lyseight F, Van den Steen N Vet Sci. 2023; 10(8).

PMID: 37624316 PMC: 10458788. DOI: 10.3390/vetsci10080529.